Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

• Hlavní autoři: Jonathan I. Silverberg (Autor), Andreas Wollenberg (Autor), Linda Stein Gold (Autor), James Del Rosso (Autor), Gil Yosipovitch (Autor), Peter Lio (Autor), Jose-Manuel Carrascosa (Autor), Gaia Gallo (Autor), Yuxin Ding (Autor), Zhenhui Xu (Autor), Marta Casillas (Autor), Evangeline Pierce (Autor), Helena Agell (Autor), Sonja Ständer (Autor)
• Médium: Kniha
• Vydáno: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials. One of the ultimate treatment goals for patients with moderate-to-severe AD is to achieve stable disease control without...